Skip to main content
SpringerLink
Log in

Bromocriptine/cabergoline/oxcarbazepine interaction

Reduced clinical efficacy leading to prolactinoma progression (first report of an interaction between cabergoline and oxcarbazepine): case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Krysiak R, Kedzia A, Okopien B.The effect of oxcarbamazepine on the clinical effectiveness of dopamine agonists in the treatment of prolactinoma. Wiadomosci Lekarskie (Warsaw, Poland: 1960) 64: 279-82, No. 4, 2011 - Poland

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bromocriptine/cabergoline/oxcarbazepine interaction. React. Wkly. 1416, 15 (2012). https://doi.org/10.2165/00128415-201214160-00046

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214160-00046

Keywords

Search

Navigation